Transplant Drugs

Human kidney anatomy
Biotech

Memo pushes kidney drug to phase 3 despite primary endpoint miss

A phase 2 trial of Memo’s kidney transplant drug candidate has missed its primary endpoint, adding to the list of setbacks in the indication.
Nick Paul Taylor Jul 25, 2025 5:30am
Organ transplant

Triple phase 3 disaster sends AlloVir shares plunging 64%

Dec 22, 2023 9:00am
Organ transplant

Immunosuppressant antibody curbs chronic transplant rejection

Apr 24, 2023 11:05am
A graphic displaying a cross-section of the kidneys

AlloVir's cell therapy tackles virus in kidney transplant trial

Feb 15, 2023 9:45am
Novartis Switzerland

Novartis stops liver transplant program due to weak phase 2 data

Oct 25, 2022 6:00am